https://www.selleckchem.com/pr....oducts/buloxibutid.h
BACKGROUND Adjuvant trastuzumab for early stage (I-III) HER2 positive breast cancer (BC) has led to statistically significant improvement in cancer outcomes but carries a risk of cardiotoxicity. Trastuzumab is discontinued early in many patients for asymptomatic changes in left ventricular ejection fraction. We evaluated the impact of early discontinuation of trastuzumab on cancer outcomes. METHODS Retrospective population-based cohort study of early BC patients treated with adjuvant trastuzumab in Ontario, Canada, 2007-2016. Four g
Curtir
Comentario
Compartilhar
